Home › Research › TREM2 and immune genetics
CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum
Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer's Disease Neuroimaging Initiative.. Neurobiology of aging, 2018-10-25
Topic: Brain proteins, microglia and lab models
Plain-language summary
TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF) when using clinical criteria to classify Alzheimer's disease (AD). The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort. Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National Institute on Aging-Alzheimer's Association research framework guidelines, which group biomarkers into those of amyloid-β deposition, tau pathology, and neurodegeneration.
What this study adds
Evidence grade: Moderate
The record lists 497 participants. In 497 people from a prospective Alzheimer's cohort grouped by spinal-fluid biomarkers, levels of soluble TREM2 (a sign of brain immune activity) were associated with markers of nerve-cell damage and tau, but not with amyloid. Levels rose over time in people with abnormal tau, but were not related to changes in thinking and memory over time.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rauchmann, B. S., Schneider-Axmann, T., Alexopoulos, P., Perneczky, R., & Alzheimer's Disease Neuroimaging Initiative. (2019). CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2018.10.022
Vancouver
Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer's Disease Neuroimaging Initiative. CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. Neurobiology of aging. 2019. doi:10.1016/j.neurobiolaging.2018.10.022. PMID: 30458365.
BibTeX
@article{rauchmann2019-30458365,
author = {Rauchmann, B. S. and Schneider-Axmann, T. and Alexopoulos, P. and Perneczky, R. and {Alzheimer's Disease Neuroimaging Initiative}},
title = {{CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum}},
journal = {Neurobiology of aging},
year = {2019},
doi = {10.1016/j.neurobiolaging.2018.10.022},
pmid = {30458365},
url = {https://doi.org/10.1016/j.neurobiolaging.2018.10.022}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort.
- Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National Institute on Aging-Alzheimer's Association research framework guidelines, which group biomarkers into those of amyloid-β deposition, tau pathology, and neurodegeneration.
- CSF sTREM2 concentrations were associated with markers of neurodegeneration and fibrillar tau pathology, but not amyloidosis; sTREM2 concentrations were increased in total tau-positive versus -negative individuals; sTREM2 was not related to cognitive and other biomarker changes over time; and sTREM2 concentrations increased over time in total tau-positive versus -negative individuals with AD pathophysiology.
- The present study provides evidence in support of sTREM2 in CSF as a marker of neuroinflammation across the spectrum of early clinical AD. sTREM2 is linked to neuronal injury and may therefore offer complementary information relevant for diagnostic purposes and novel treatment approaches targeting the immune system in AD.
Why it matters
In 497 people from a prospective Alzheimer's cohort grouped by spinal-fluid biomarkers, levels of soluble TREM2 (a sign of brain immune activity) were associated with markers of nerve-cell damage and tau, but not with amyloid. Levels rose over time in people with abnormal tau, but were not related to changes in thinking and memory over time. The authors see it as a possible complementary marker of neuroinflammation; this observational study does not show it can diagnose, treat or prevent Alzheimer's.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Participants497
- Evidence strengthModerate
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of aging) |
| Journal's citation record | 3 / 4 | Neurobiology of Aging: journal h-index 263 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 497 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 73 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.1 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 2 / 6 | Cited 2.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 16 other studies in this library |
| Still being cited | 2 / 4 | Cited 24 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Robert Perneczky: h-index 73 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Imperial College London: institution h-index 1,744 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30458365) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neurobiolaging.2018.10.022
- PubMed: 30458365
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 37.
Later studies that cite this one
16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.